#United States #New York #Class Action #Pomerantz LLP #Biohaven Ltd

Pomerantz Law Firm Files Class Action Against Biohaven Ltd.

On July 27, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Biohaven Ltd. (traded under NYSE: BHVN) and several of its top officers. This lawsuit has been officially registered with the United States District Court for the District of Connecticut, bearing the docket number 25-cv-01120. The class action seeks to represent all individuals and entities who acquired Biohaven securities between March 24, 2023, and May 14, 2025.

The core of the lawsuit is aimed at addressing alleged violations of federal securities laws. Investors claim that the company and its executives made misleading statements about the viability of its drug candidate, troriluzole, particularly as a treatment for spinocerebellar ataxia (SCA) and bipolar disorder. Key sections of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), and Rule 10b-5, which protect investors from deceptive practices, serve as the legal foundation for this action.

Investors who purchased Biohaven securities during the specified period have until September 12, 2025, to apply for the role of Lead Plaintiff in this class action. Those interested can find the Complaint and further information through Pomerantz’s website.

The Allegations Against Biohaven

Biohaven is known as a biopharmaceutical company focused on developing therapies targeting challenges in immunology, neuroscience, and oncology. The company has been working on several products, most notably, troriluzole, which was touted for its potential efficacy against conditions like SCA. The legal troubles began following a Phase 3 trial in May 2022, which ultimately did not meet its primary endpoint. Despite this setback, Biohaven and its leaders continued to promote the drug as a promising candidate, basing their claims on additional post-hoc analyses.

In May 2023, Biohaven took a step further by submitting a New Drug Application (NDA) for troriluzole to the FDA, and subsequently, they also received notice that the European Medicines Agency (EMA) accepted their Marketing Authorization Application for the same drug in October of the same year. Throughout this time, however, numerous misleading statements related to their business operations and drug approval prospects have emerged, suggesting that the executives overstated the scientific data backing leurs produits.

The lawsuit cites a significant drop in Biohaven's stock price following major announcements, including the FDA's rejection of the NDA for troriluzole in July 2023, leading to a 22.61% plunge in stock value from $23.80 to $18.42 per share. A pattern of decline continued after further disappointing news regarding their bipolar drug candidate, BHV-7000. A release on March 3, 2025, stated that new downturns in market confidence left Biohaven's stock at $32.06 by the end of that reporting day, a 13.77% drop.

The culmination of events has led to mounting pressures on Biohaven that were exacerbated by reports of withdrawal of their MAA with the EMA, resulting in further stock depreciation. Following announcements in April 2025, the company saw another significant 15.21% fall, closing at $19.84 per share. On May 14, 2025, as news about delays in the drug review process emerged, stock prices fell to $15.82, marking a further drop of 19.53%.

About Pomerantz LLP

Pomerantz LLP operates out of various major cities including New York, Chicago, and Los Angeles. It is recognized as a leading firm specializing in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm has established a solid reputation for championing the rights of victims affected by securities fraud and corporate misconduct, accumulating billions in damages on behalf of its class members.

As this class action unfolds, investors affected by Biohaven's practices await clarity and accountability for what they allege are deception and breaches of trust. Investors interested in participating in this action are encouraged to reach out to Pomerantz LLP for more guidance and information on legal proceedings ahead.